{"id":26623,"date":"2025-11-05T19:57:28","date_gmt":"2025-11-05T12:57:28","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=26623"},"modified":"2025-11-06T17:54:27","modified_gmt":"2025-11-06T10:54:27","slug":"oxacillin-sodium-monohydrate","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/oxacillin-sodium-monohydrate\/","title":{"rendered":"Oxacillin Sodium Monohydrate"},"content":{"rendered":"

Edition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n

Action and use<\/p>\n

Penicillin antibacterial.<\/p>\n

Ph Eur<\/p>\n

DEFINITION<\/h2>\n
Sodium (2S,5R,6R)-3,3-dimethyl-6-[[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino]-7-oxo-4-thia-1- azabicyclo[3.2.0]heptane-2-carboxylate monohydrate.
\nSemi-synthetic product derived from a fermentation product.<\/p>\n
Content<\/strong><\/p>\n
95.0 per cent to 102.0 per cent (anhydrous substance).<\/p>\n

CHARACTERS<\/h2>\n
Appearance<\/h3>\n
White or almost white powder.<\/p>\n
Solubility<\/h3>\n
Freely soluble in water, soluble in methanol, practically insoluble in methylene chloride.<\/p>\n
IDENTIFICATION<\/h2>\n
A. Infrared absorption spectrophotometry (2.2.24).<\/p>\n
Comparison\u00a0 oxacillin sodium monohydrate CRS.<\/p>\n
B. It gives reaction (a) of sodium (2.3.1).<\/p>\n
TESTS<\/h2>\n
Appearance of solution<\/h3>\n
The solution is clear (2.2.1) and its absorbance (2.2.25) at 430 nm is not greater than 0.10. Dissolve 2.50 g in water R and dilute to 25.0 mL with the same solvent.<\/p>\n
pH (2.2.3)<\/strong><\/p>\n
4.5 to 7.5.<\/p>\n
Dissolve 0.30 g in carbon dioxide-free water R and dilute to 10 mL with the same solvent.<\/p>\n
Specific optical rotation (2.2.7)<\/strong><\/p>\n
+ 196 to + 212 (anhydrous substance).<\/p>\n
Dissolve 0.250 g in water R and dilute to 25.0 mL with the same solvent.<\/p>\n
Related substances<\/h3>\n
Liquid chromatography (2.2.29).<\/p>\n
Test solution (a)\u00a0 Dissolve 50.0 mg of the substance to be examined in the mobile phase and dilute to 50.0 mL with the mobile phase.<\/p>\n
Test solution (b)\u00a0 Dilute 5.0 mL of test solution (a) to 50.0 mL with the mobile phase.<\/p>\n
Reference solution (a)\u00a0 Dissolve 50.0 mg of oxacillin sodium monohydrate CRS in the mobile phase and dilute to 50.0 mL with the mobile phase. Dilute 5.0 mL of the solution to 50.0 mL with the mobile phase.<\/p>\n
Reference solution (b)\u00a0 Dilute 5.0 mL of test solution (b) to 50.0 mL with the mobile phase.<\/p>\n
Reference solution (c)\u00a0 Dissolve 5 mg of cloxacillin sodium CRS (impurity E) and 5 mg of oxacillin sodium monohydrate CRS in the mobile phase and dilute to 50.0 mL with the mobile phase.<\/p>\n
Reference solution (d)\u00a0 In order to prepare impurities B and D in situ, dissolve 25 mg of the substance to be examined in 1 mL of 0.05 M sodium hydroxide, allow to stand for 3 min, then dilute to 100 mL with the mobile phase. Inject immediately.<\/p>\n
Reference solution (e)\u00a0 Dissolve 5 mg of oxacillin for peak identification CRS (containing impurities E, F, G, I and J) in 5 mL of the mobile phase.<\/p>\n
Column:<\/p>\n
\u2014 size: l = 0.25 m, \u00d8 = 4.0 mm;<\/p>\n
\u2014 stationary phase: octadecylsilyl silica gel for chromatography R (5 \u00b5m).<\/p>\n
Mobile phase\u00a0 Mix 25 volumes of acetonitrile R and 75 volumes of a 2.7 g\/L solution of potassium dihydrogen phosphate R previously adjusted to pH 5.0 with dilute sodium hydroxide solution R.<\/p>\n
Flow rate\u00a0 1.0 mL\/min.<\/p>\n
Detection\u00a0 Spectrophotometer at 225 nm.<\/p>\n
Injection\u00a0 20 \u00b5L of test solution (a) and reference solutions (b), (c), (d) and (e).<\/p>\n
Run time\u00a0 7 times the retention time of oxacillin.<\/p>\n
Identification of impurities:<\/p>\n
\u2014 in the chromatogram obtained with reference solution (d), the 2 principal peaks eluting before the main peak are due to impurities B and D respectively;<\/p>\n
\u2014 use the chromatogram supplied with oxacillin for peak identification CRS and the chromatogram obtained with reference solution (e) to identify the peaks due to impurities E, F, G, I and J.<\/p>\n
Relative retention\u00a0 With reference to oxacillin (retention time = about 5 min): impurity A = about 0.3; impurity B (isomer 1) = about 0.4; impurity B (isomer 2) = about 0.5; impurity C = about 0.65; impurity D (2 epimers) = about 0.9; impurity E = about 1.5; impurity F = about 1.9; impurity G = about 2.1; impurity I = about 3.8; impurity J = about 5.8.<\/p>\n
System suitability:<\/p>\n
\u2014 resolution: minimum 2.5 between the peaks due to oxacillin and impurity E in the chromatogram obtained with reference solution (c);<\/p>\n
\u2014 the chromatogram obtained with reference solution (e) is similar to the chromatogram supplied with oxacillin for peak identification CRS. Limits:<\/p>\n
\u2014 impurity B: for the sum of the areas of the 2 isomer peaks, not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (1.5 per cent);<\/p>\n
\u2014 impurity E: not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent);<\/p>\n
\u2014 impurities D (sum of the 2 epimers), F, G, I, J: for each impurity, not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent);<\/p>\n
\u2014 any other impurity: for each impurity, not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent);<\/p>\n
\u2014 total: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (b) (3.0 per cent);<\/p>\n
\u2014 disregard limit: 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent).<\/p>\n
Ethyl acetate and butyl acetate<\/h3>\n
Head-space gas chromatography (2.2.28).<\/p>\n
Test solution\u00a0 Dissolve 0.200 g of the substance to be examined in 6.0 mL of water R.<\/p>\n
Reference solution\u00a0 Dissolve 83 mg of butyl acetate R and 83 mg of ethyl acetate R in water R and dilute to 250.0 mL with the same solvent. Use 6.0 mL of this solution.<\/p>\n
Close the vials immediately with a rubber membrane stopper coated with polytetrafluoroethylene and secured with an aluminium crimp cap. Mix to obtain a homogeneous solution.<\/p>\n
Column:<\/p>\n
\u2014 material: fused silica;<\/p>\n
\u2014 size: l = 50 m, \u00d8 = 0.32 mm;<\/p>\n
\u2014 stationary phase: methylpolysiloxane R (film thickness 5 \u00b5m).<\/p>\n
Carrier gas helium for chromatography R. Flow rate 2 mL\/min.<\/p>\n
Static head-space conditions that may be used:<\/p>\n
\u2014 equilibration temperature: 80 \u00b0C;<\/p>\n
\u2014 equilibration time: 60 min;<\/p>\n
\u2014 transfer-line temperature: 140 \u00b0C;<\/p>\n
\u2014 pressurisation time: 30 s.<\/p>\n
Temperature:<\/p>\n\n\n\n\n\n\n\n\n
<\/td>\n Time (min)<\/strong><\/td>\n Temperature (\u00b0C)<\/strong><\/td>\n<\/tr>\n
Column<\/td>\n 0 – 6<\/td>\n 70<\/td>\n<\/tr>\n
<\/td>\n 6 – 16<\/td>\n 70 \u2192 220<\/td>\n<\/tr>\n
<\/td>\n 16 – 18<\/td>\n 220<\/td>\n<\/tr>\n
Injection port<\/td>\n 140<\/td>\n<\/tr>\n
Detector<\/td>\n 250<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Detection\u00a0 Flame ionisation.<\/p>\n
Retention time\u00a0 Ethyl acetate = about 10 min; butyl acetate = about 15.5 min.<\/p>\n
Limits:<\/p>\n
\u2014 butyl acetate: maximum 1.0 per cent;<\/p>\n
\u2014 ethyl acetate: maximum 1.0 per cent.<\/p>\n
N,N-Dimethylaniline (2.4.26, Method B) Maximum 20 ppm.<\/p>\n
2- Ethylhexanoic acid (2.4.28) Maximum 0.8 per cent.<\/p>\n
Water (2.5.12)<\/strong><\/p>\n
3- 5 per cent to 5.0 per cent, determined on 0.300 g.<\/p>\n
Bacterial endotoxins (2.6.14)<\/strong><\/p>\n
Less than 0.20 IU\/mg, if intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins.<\/p>\n
ASSAY<\/h2>\n
Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.<\/p>\n
Injection\u00a0 Test solution (b) and reference solution (a).<\/p>\n
Calculate the percentage content of C_{19<\/sub>H_{18<\/sub>N_{3<\/sub>NaO_{5<\/sub>S taking into account the assigned content of oxacillin sodium monohydrate CRS.<\/p>\n}}}}
IMPURITIES<\/h2>\n
Specified impurities\u00a0 B, D, E, F, G, I, J.<\/em><\/p>\n
Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10.<\/em><\/p>\n
Control of impurities in substances for pharmaceutical use)\u00a0 A, C.<\/em><\/p>\n
$\"Oxacillin$ <\/p>\n
A. (2S,5R,6R)-6-amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (6- aminopenicillanic acid),<\/p>\n
$\"Oxacillin$ <\/p>\n
B. (4S)-2-[carboxy[[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino]methyl]-5,5-dimethylthiazolidine-4-\u00a0 carboxylic acid (penicilloic acids of oxacillin),<\/p>\n
$\"Oxacillin$ <\/p>\n
C. 5-methyl-3-phenylisoxazole-4-carboxylic acid,<\/p>\n
$\"Oxacillin$ <\/p>\n
D. (2RS,4S)-5,5-dimethyl-2-[[[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino]methyl]thiazolidine-4-\u00a0 carboxylic acid (penilloic acids of oxacillin),<\/p>\n
$\"Oxacillin$ <\/p>\n
E. (2S,5R,6R)-6-[[[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-\u00a0 azabicyclo[3.2.0]heptane-2-carboxylic acid (cloxacillin),<\/p>\n
$\"Oxacillin$ <\/p>\n
F. (2R,5R,6R)-3,3-dimethyl-6-[[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino]-7-oxo-4-thia-1-\u00a0 azabicyclo[3.2.0]heptane-2-carbothioic acid (thiooxacillin),<\/p>\n
$\"Oxacillin$ <\/p>\n
G. (2S,5R,6R)-6-[[[3-(chlorophenyl)-5-methylisoxazol-4-yl]carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-\u00a0 azabicyclo[3.2.0]heptane-2-carboxylic acid (cloxacillin isomer),<\/p>\n
$\"Oxacillin$ <\/p>\n
I. (2S,5R,6R)-6-[[(2S,5R,6R)-3,3-dimethyl-6-[[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino]-7-oxo-4-\u00a0 thia-1-azabicyclo[3.2.0]heptane-2-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-\u00a0 carboxylic acid (6-APA oxacillin amide),<\/p>\n
$\"Oxacillin$ <\/p>\n
J. (2S,5R,6R)-6-[[(2R)-[(2R,4S)-4-carboxy-5,5-dimethylthiazolidin-2-yl][[(5-methyl-3-phenylisoxazol-4- yl)carbonyl]amino]acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (ozolamide of 6-APA dimer).<\/p>\n
\n
Ph Eur<\/p>\n","protected":false},"excerpt":{"rendered":"
Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Penicillin antibacterial. Ph Eur DEFINITION Sodium (2S,5R,6R)-3,3-dimethyl-6-[[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino]-7-oxo-4-thia-1- azabicyclo[3.2.0]heptane-2-carboxylate monohydrate. Semi-synthetic product derived from a fermentation product. Content 95.0 per cent to 102.0 per cent (anhydrous substance). CHARACTERS Appearance White or almost white powder. Solubility Freely soluble in water, soluble in methanol, practically insoluble in methylene…<\/p>\n","protected":false},"author":5,"featured_media":26625,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-26623","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/26623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=26623"}],"version-history":[{"count":4,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/26623\/revisions"}],"predecessor-version":[{"id":27387,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/26623\/revisions\/27387"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/26625"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=26623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=26623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=26623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

<\/td>\n	Time (min)<\/strong><\/td>\n	Temperature (\u00b0C)<\/strong><\/td>\n<\/tr>\n
Column<\/td>\n	0 – 6<\/td>\n	70<\/td>\n<\/tr>\n
<\/td>\n	6 – 16<\/td>\n	70 \u2192 220<\/td>\n<\/tr>\n
<\/td>\n	16 – 18<\/td>\n	220<\/td>\n<\/tr>\n
Injection port<\/td>\n	140<\/td>\n<\/tr>\n
Detector<\/td>\n	250<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Detection\u00a0 Flame ionisation.<\/p>\n Retention time\u00a0 Ethyl acetate = about 10 min; butyl acetate = about 15.5 min.<\/p>\n Limits:<\/p>\n \u2014 butyl acetate: maximum 1.0 per cent;<\/p>\n \u2014 ethyl acetate: maximum 1.0 per cent.<\/p>\n N,N-Dimethylaniline (2.4.26, Method B) Maximum 20 ppm.<\/p>\n 2- Ethylhexanoic acid (2.4.28) Maximum 0.8 per cent.<\/p>\n Water (2.5.12)<\/strong><\/p>\n 3- 5 per cent to 5.0 per cent, determined on 0.300 g.<\/p>\n Bacterial endotoxins (2.6.14)<\/strong><\/p>\n Less than 0.20 IU\/mg, if intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins.<\/p>\n ASSAY<\/h2>\n Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.<\/p>\n Injection\u00a0 Test solution (b) and reference solution (a).<\/p>\n Calculate the percentage content of C_{19<\/sub>H_{18<\/sub>N_{3<\/sub>NaO_{5<\/sub>S taking into account the assigned content of oxacillin sodium monohydrate CRS.<\/p>\n}}}} IMPURITIES<\/h2>\n Specified impurities\u00a0 B, D, E, F, G, I, J.<\/em><\/p>\n Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10.<\/em><\/p>\n Control of impurities in substances for pharmaceutical use)\u00a0 A, C.<\/em><\/p>\n $\"Oxacillin$ <\/p>\n A. (2S,5R,6R)-6-amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (6- aminopenicillanic acid),<\/p>\n $\"Oxacillin$ <\/p>\n B. (4S)-2-[carboxy[[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino]methyl]-5,5-dimethylthiazolidine-4-\u00a0 carboxylic acid (penicilloic acids of oxacillin),<\/p>\n $\"Oxacillin$ <\/p>\n C. 5-methyl-3-phenylisoxazole-4-carboxylic acid,<\/p>\n $\"Oxacillin$ <\/p>\n D. (2RS,4S)-5,5-dimethyl-2-[[[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino]methyl]thiazolidine-4-\u00a0 carboxylic acid (penilloic acids of oxacillin),<\/p>\n $\"Oxacillin$ <\/p>\n E. (2S,5R,6R)-6-[[[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-\u00a0 azabicyclo[3.2.0]heptane-2-carboxylic acid (cloxacillin),<\/p>\n $\"Oxacillin$ <\/p>\n F. (2R,5R,6R)-3,3-dimethyl-6-[[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino]-7-oxo-4-thia-1-\u00a0 azabicyclo[3.2.0]heptane-2-carbothioic acid (thiooxacillin),<\/p>\n $\"Oxacillin$ <\/p>\n G. (2S,5R,6R)-6-[[[3-(chlorophenyl)-5-methylisoxazol-4-yl]carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-\u00a0 azabicyclo[3.2.0]heptane-2-carboxylic acid (cloxacillin isomer),<\/p>\n $\"Oxacillin$ <\/p>\n I. (2S,5R,6R)-6-[[(2S,5R,6R)-3,3-dimethyl-6-[[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino]-7-oxo-4-\u00a0 thia-1-azabicyclo[3.2.0]heptane-2-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-\u00a0 carboxylic acid (6-APA oxacillin amide),<\/p>\n $\"Oxacillin$ <\/p>\n J. (2S,5R,6R)-6-[[(2R)-[(2R,4S)-4-carboxy-5,5-dimethylthiazolidin-2-yl][[(5-methyl-3-phenylisoxazol-4- yl)carbonyl]amino]acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (ozolamide of 6-APA dimer).<\/p>\n \n Ph Eur<\/p>\n","protected":false},"excerpt":{"rendered":" Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Penicillin antibacterial. Ph Eur DEFINITION Sodium (2S,5R,6R)-3,3-dimethyl-6-[[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino]-7-oxo-4-thia-1- azabicyclo[3.2.0]heptane-2-carboxylate monohydrate. Semi-synthetic product derived from a fermentation product. Content 95.0 per cent to 102.0 per cent (anhydrous substance). CHARACTERS Appearance White or almost white powder. Solubility Freely soluble in water, soluble in methanol, practically insoluble in methylene…<\/p>\n","protected":false},"author":5,"featured_media":26625,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-26623","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/26623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=26623"}],"version-history":[{"count":4,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/26623\/revisions"}],"predecessor-version":[{"id":27387,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/26623\/revisions\/27387"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/26625"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=26623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=26623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=26623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Appearance<\/h3>\nWhite or almost white powder.<\/p>\n

Solubility<\/h3>\nFreely soluble in water, soluble in methanol, practically insoluble in methylene chloride.<\/p>\n

IDENTIFICATION<\/h2>\nA. Infrared absorption spectrophotometry (2.2.24).<\/p>\nComparison\u00a0 oxacillin sodium monohydrate CRS.<\/p>\nB. It gives reaction (a) of sodium (2.3.1).<\/p>\n

TESTS<\/h2>\n

Appearance<\/h3>\n
White or almost white powder.<\/p>\n

Solubility<\/h3>\n
Freely soluble in water, soluble in methanol, practically insoluble in methylene chloride.<\/p>\n

IDENTIFICATION<\/h2>\n
A. Infrared absorption spectrophotometry (2.2.24).<\/p>\n
Comparison\u00a0 oxacillin sodium monohydrate CRS.<\/p>\n
B. It gives reaction (a) of sodium (2.3.1).<\/p>\n